UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

Modern pathology, 2020-09, Vol.33 (9), p.1746-1752

2020

Volltextzugriff (PDF)

Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision

Modern pathology, 2021-08, Vol.34 (8), p.1495-1506

2021

Volltextzugriff (PDF)

Histopathologic features of breast cancer in Li–Fraumeni syndrome

Modern pathology, 2021-03, Vol.34 (3), p.542-548

2021

Volltextzugriff (PDF)

Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?

Annals of surgical oncology, 2023-10, Vol.30 (10), p.6061-6069

2023

Volltextzugriff (PDF)

Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations

NPJ precision oncology, 2024-02, Vol.8 (1), p.33-33, Article 33

2024

Volltextzugriff (PDF)

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

JAMA oncology, 2022-04, Vol.8 (4), p.1

2022

Volltextzugriff (PDF)

Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry

Modern pathology, 2023-01, Vol.36 (1), p.100032-100032, Article 100032

2023

Volltextzugriff (PDF)

Is Surgical Excision of Focal Atypical Ductal Hyperplasia Warranted? Experience at a Tertiary Care Center

Annals of surgical oncology, 2023-07, Vol.30 (7), p.4087-4094

2023

Volltextzugriff (PDF)

ASO Visual Abstract: Is Surgical Excision of Focal Atypical Ductal Hyperplasia Warranted? Experience at a Tertiary Care Center

Annals of surgical oncology, 2023-07, Vol.30 (7), p.4095-4096

2023

Volltextzugriff (PDF)

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging

Archives of pathology & laboratory medicine (1976), 2021-09, Vol.145 (9), p.1132-1137

2021

Volltextzugriff (PDF)

Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy

American journal of clinical pathology, 2017-09, Vol.148 (3), p.243-250

2017

Volltextzugriff (PDF)

Fibromatosis of the Breast

American journal of clinical pathology, 2017-09, Vol.148 (3), p.243-250

2017

Volltextzugriff (PDF)

Mixed and Purely Hyperechoic Breast Masses: A Radiologic-Pathologic Review

Journal of breast imaging, 2023-02, Vol.5 (1), p.85-92

2023

Volltextzugriff (PDF)

The impact of MYC amplification on clinicopathologic features and prognosis of radiation-associated angiosarcomas of the breast

Histopathology, 2021-09, Vol.79 (5), p.836-846

2021

Volltextzugriff (PDF)

Abstract P1-02-02: Examination of low Her2 expression in breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-02-02

2022

Volltextzugriff (PDF)

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging

Archives of pathology & laboratory medicine (1976), 2021-09, Vol.145 (9)

2021

Volltextzugriff (PDF)

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Proceedings of the National Academy of Sciences - PNAS, 2013-08, Vol.110 (35), p.14372-14377

2013

Volltextzugriff (PDF)

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

The Journal of clinical investigation, 2013-03, Vol.123 (3), p.1348-1358

2013

Volltextzugriff (PDF)

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1202-1209

2014

Volltextzugriff (PDF)

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

Breast cancer research : BCR, 2013-07, Vol.15 (4), p.R55-R55, Article R55

2013

Volltextzugriff (PDF)

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer

The Journal of clinical investigation, 2014-12, Vol.124 (12), p.5490-5502

2014

Volltextzugriff (PDF)

Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma

Genes chromosomes & cancer, 2024-05, Vol.63 (5), p.e23240-n/a

2024

Volltextzugriff (PDF)

A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1024-1024

2012

Volltextzugriff (PDF)

TGF-[Beta] Inhibition enhances chemotherapy action against triple-negative breast cancer

The Journal of clinical investigation, 2013-03, Vol.123 (3), p.1348

2013

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision

Histopathologic features of breast cancer in Li–Fraumeni syndrome

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?

Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry

Is Surgical Excision of Focal Atypical Ductal Hyperplasia Warranted? Experience at a Tertiary Care Center

ASO Visual Abstract: Is Surgical Excision of Focal Atypical Ductal Hyperplasia Warranted? Experience at a Tertiary Care Center

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging

Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy

Fibromatosis of the Breast

Mixed and Purely Hyperechoic Breast Masses: A Radiologic-Pathologic Review

The impact of MYC amplification on clinicopathologic features and prognosis of radiation-associated angiosarcomas of the breast

Abstract P1-02-02: Examination of low Her2 expression in breast cancer

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer

Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma

A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer

TGF-[Beta] Inhibition enhances chemotherapy action against triple-negative breast cancer

Suchergebnisse filtern